Ann: OVARIAN CANCER CLINICAL STUDY RESULTS, page-42

isn't something that will be able to be sold at a chemist like a pregnancy test. It would be hard to widely sell a blood test that is 10% of the time wrong

Why would it be sold at a chemist!!

The most important results in any trial of a cancer diagnostic test are “sensitivity” and “specificity”. Sensitivity refers to the percentage of accurately identified cancers (true positive rate) and specificity refers
to the percentage of correct non-cancers identified (true negative result). A good new generation diagnostic test should have both of these scores in the high range (above 80%). Using such a test would ensure very low rates of both false positives or false negatives. An overall score of accuracy can be
generated from this and is called “ROC-AUC”. A perfect test would have an AUC=1.0, an excellent test AUC=0.9-0.99, a good test AUC=0.8-0.89, and a useless test AUC=0.5.


"likely need to be improved with new evidence in another clinical trial. "

The trial involving 348 samples (200 women with ovarian cancer and 148 controls) found the test to have both high specificity (87%) and high sensitivity (90%),

“With high levels of accuracy shown to all stages of ovarian cancer, our test may offer a substantial improvement over existing ovarian cancer blood tests using CA125 where both sensitivity and specificity are lower.” said Dr Leearne Hinch, Chief Executive Officer at BARD1 Life Sciences Ltd, “Our test should greatly improve the accurate detection of cancer at all stages with few false positives.”